1
|
Blonski W, Slone S, Jacobs JW. Lichen planus esophagitis. Curr Opin Gastroenterol 2023; 39:308-314. [PMID: 37097828 DOI: 10.1097/mog.0000000000000936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/26/2023]
Abstract
PURPOSE OF REVIEW Dysphagia is one of the most common reasons for patients' visits to a gastroenterologist. Esophageal lichen planus (ELP) has historically been felt to be a rare disease, when in fact it is often misdiagnosed and unrecognized. Often first diagnosed as an unusual esophagitis, all gastroenterologists will see ELP in their practice, and need to be able to recognize this condition. RECENT FINDINGS Although there is still a relative paucity of data on this condition, this article will update the typical presenting symptoms, endoscopic findings, and ways to differentiate ELP from other inflammatory mucosal diseases. There is still no standardized treatment algorithm, but we will also present the most recent treatment approaches. SUMMARY It is critical that physicians maintain an increased awareness of ELP and have a high clinical suspicion in the appropriate patients. While management remains challenging, it is important to treat both the inflammatory and stricturing components of the disease. A multidisciplinary approach is also often required, utilizing dermatologists, gynecologists, and dentists who are familiar with managing patients with LP.
Collapse
Affiliation(s)
- Wojciech Blonski
- Joy McCann Culverhouse Center for Swallowing Disorders, Division of Digestive Diseases and Nutrition
- Division of Gastroenterology, James A. Haley Veterans Affairs Hospital, University of South Florida, Tampa, Florida, USA
| | - Samuel Slone
- Joy McCann Culverhouse Center for Swallowing Disorders, Division of Digestive Diseases and Nutrition
| | - John W Jacobs
- Joy McCann Culverhouse Center for Swallowing Disorders, Division of Digestive Diseases and Nutrition
| |
Collapse
|
2
|
Abstract
Achalasia is a rare disease of the esophagus with impaired relaxation of the lower esophageal sphincter and aperistalsis. The etiology is unknown but speculations include a viral or autoimmune etiology. All specialists dealing with swallowing and esophageal diseases should recognize the classic symptoms of dysphagia for solids/liquids, regurgitation, and choking, especially at night. High-resolution manometry is critical for the diagnosis with endoscopy and barium esophagram having a supportive role. The disease cannot be cured but most can return to near normal swallowing and a regular diet with appropriate therapy. Treatment includes smooth muscle relaxants, botulinum toxin injections to the lower sphincter, pneumatic dilation, Heller myotomy, and peroral endoscopic myotomy. One treatment does not fit all and a tailored approach through a multidiscipline team will give the best long-term outcomes.
Collapse
Affiliation(s)
- Wojciech Blonski
- Division of Gastroenterology, James A. Haley VA Hospital, Tampa, FL, USA
- Division of Gastroenterology and Nutrition, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd, MDC 72, Tampa, FL, 33612, USA
| | - Samuel Slone
- Division of Gastroenterology and Nutrition, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd, MDC 72, Tampa, FL, 33612, USA
| | - Joel E Richter
- Division of Gastroenterology and Nutrition, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Blvd, MDC 72, Tampa, FL, 33612, USA.
- Joy McCann Culverhouse Center for Esophageal Diseases, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
| |
Collapse
|
3
|
Slone S, Anthony SR, Green LC, Nieman ML, Alam P, Wu X, Roy S, Aube J, Xu L, Lorenz JN, Owens AP, Kanisicak O, Tranter M. HuR inhibition reduces post-ischemic cardiac remodeling by dampening acute inflammatory gene expression and the innate immune response. bioRxiv 2023:2023.01.17.524420. [PMID: 36711986 PMCID: PMC9882229 DOI: 10.1101/2023.01.17.524420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Myocardial ischemia/reperfusion (I/R) injury and the resulting cardiac remodeling is a common cause of heart failure. The RNA binding protein Human Antigen R (HuR) has been previously shown to reduce cardiac remodeling following both I/R and cardiac pressure overload, but the full extent of the HuR-dependent mechanisms within cells of the myocardium have yet to be elucidated. In this study, we applied a novel small molecule inhibitor of HuR to define the functional role of HuR in the acute response to I/R injury and gain a better understanding of the HuR-dependent mechanisms during post-ischemic myocardial remodeling. Our results show an early (two hours post-I/R) increase in HuR activity that is necessary for early inflammatory gene expression by cardiomyocytes in response to I/R. Surprisingly, despite the reductions in early inflammatory gene expression at two hours post-I/R, HuR inhibition has no effect on initial infarct size at 24-hours post-I/R. However, in agreement with previously published work, we do see a reduction in pathological remodeling and preserved cardiac function at two weeks post-I/R upon HuR inhibition. RNA-sequencing analysis of neonatal rat ventricular myocytes (NRVMs) at two hours post-LPS treatment to model damage associated molecular pattern (DAMP)-mediated activation of toll like receptors (TLRs) demonstrates a broad HuR-dependent regulation of pro-inflammatory chemokine and cytokine gene expression in cardiomyocytes. We show that conditioned media from NRVMs pre-treated with HuR inhibitor loses the ability to induce inflammatory gene expression in bone marrow derived macrophages (BMDMs) compared to NRVMs treated with LPS alone. Functionally, HuR inhibition in NRVMs also reduces their ability to induce endocrine migration of peripheral blood monocytes in vitro and reduces post-ischemic macrophage infiltration to the heart in vivo. In summary, these results suggest a HuR-dependent expression of pro-inflammatory gene expression by cardiomyocytes that leads to subsequent monocyte recruitment and macrophage activation in the post-ischemic myocardium.
Collapse
|
4
|
Green LC, Slone S, Anthony SR, Guarnieri AR, Parkins S, Shearer SM, Nieman ML, Roy S, Aube J, Wu X, Xu L, Kanisicak O, Tranter M. HuR-dependent expression of Wisp1 is necessary for TGFβ-induced cardiac myofibroblast activity. J Mol Cell Cardiol 2023; 174:38-46. [PMID: 36372279 PMCID: PMC9868076 DOI: 10.1016/j.yjmcc.2022.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Revised: 10/17/2022] [Accepted: 10/17/2022] [Indexed: 11/13/2022]
Abstract
Cardiac fibrosis is regulated by the activation and phenotypic switching of quiescent cardiac fibroblasts to active myofibroblasts, which have extracellular matrix (ECM) remodeling and contractile functions which play a central role in cardiac remodeling in response to injury. Here, we show that expression and activity of the RNA binding protein HuR is increased in cardiac fibroblasts upon transformation to an active myofibroblast. Pharmacological inhibition of HuR significantly blunts the TGFβ-dependent increase in ECM remodeling genes, total collagen secretion, in vitro scratch closure, and collagen gel contraction in isolated primary cardiac fibroblasts, suggesting a suppression of TGFβ-induced myofibroblast activation upon HuR inhibition. We identified twenty-four mRNA transcripts that were enriched for HuR binding following TGFβ treatment via photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP). Eleven of these HuR-bound mRNAs also showed significant co-expression correlation with HuR, αSMA, and periostin in primary fibroblasts isolated from the ischemic-zone of infarcted mouse hearts. Of these, WNT1-inducible signaling pathway protein-1 (Wisp1; Ccn4), was the most significantly associated with HuR expression in fibroblasts. Accordingly, we found Wisp1 expression to be increased in cardiac fibroblasts isolated from the ischemic-zone of mouse hearts following ischemia/reperfusion, and confirmed Wisp1 expression to be HuR-dependent in isolated fibroblasts. Finally, addition of exogenous recombinant Wisp1 partially rescued myofibroblast-induced collagen gel contraction following HuR inhibition, demonstrating that HuR-dependent Wisp1 expression plays a functional role in HuR-dependent MF activity downstream of TGFβ. In conclusion, HuR activity is necessary for the functional activation of primary cardiac fibroblasts in response to TGFβ, in part through post-transcriptional regulation of Wisp1.
Collapse
Affiliation(s)
- Lisa C Green
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America; Department of Pharmacology & Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Samuel Slone
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America; Department of Pharmacology & Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Sarah R Anthony
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Adrienne R Guarnieri
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Sharon Parkins
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Shannon M Shearer
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America; Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Michelle L Nieman
- Department of Pharmacology & Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Sudeshna Roy
- Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States of America
| | - Jeffrey Aube
- Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States of America
| | - Xiaoqing Wu
- Department of Molecular Biosciences, University of Kansas, Lawrence, KS, United States of America
| | - Liang Xu
- Department of Molecular Biosciences, University of Kansas, Lawrence, KS, United States of America
| | - Onur Kanisicak
- Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America
| | - Michael Tranter
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States of America.
| |
Collapse
|
5
|
Slone S, Kumar A, Jacobs J, Velanovich V, Richter JE. Accuracy of Achalasia Quality of Life and Eckardt scores for assessment of clinical improvement post treatment for achalasia. Dis Esophagus 2021; 34:5900199. [PMID: 32875315 DOI: 10.1093/dote/doaa080] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 04/23/2020] [Accepted: 05/03/2020] [Indexed: 02/07/2023]
Abstract
Achalasia Quality of Life (ASQ) and Eckardt scores are two patient-reported instruments widely used to assess symptom severity in achalasia patients. ASQ is validated and reliable. Although Eckardt is commonly used, it has not been rigorously assessed for validity or reliability. This study aims to evaluate (i) the accuracy of Eckardt and ASQ for assessing improvement post-treatment (predictive validity), (ii) accuracy of Eckardt and ASQ for assessing improvement post-treatment with pneumatic dilatation (PD) versus surgical myotomy (predictive validity), and (iii) convergent validity of Eckardt and ASQ tools. Patients with achalasia treated between 2011 and 2018 were eligible. Both instruments were administered by telephone. Treatment failure was determined by the review of medical records by two clinicians. The predictive ability of ASQ and Eckardt instruments in identifying treatment successes and failures was determined using receiver operating characteristics analysis and summarized as area under the curve (AUC). A total of 106 patients met inclusion criteria with 39 PD, 51 Heller myotomy, and 16 per-oral endoscopic myotomy. A review of medical records and esophageal testing revealed 13 failures (12%). AUC for Eckardt was 0.96 (95% confidence interval [CI] 0.87-0.99] and ASQ 0.97 (95% CI 0.92-0.99). The Eckardt cutoff 4, and ASQ, cutoff 15, were 94% and 87% accurate in identifying treatment successes versus failures, respectively. The correlation coefficient between the two tools was 0.85. In conclusions, (i) ASQ and Eckardt scores are valid and reliable tools to assess symptom severity in achalasia patients, (ii) both instruments accurately classify treatment successes versus failures, and (iii) the choice of tool should be informed by the physicians and patients' values and preferences and repeat physiologic testing may be reserved for treatment failures with either instrument and patients classified, as treatment successes may be spared routine physiologic testing in the long term.
Collapse
Affiliation(s)
| | | | - John Jacobs
- Division of Digestive Diseases and Nutrition.,Joy McCann Culverhouse Center for Swallowing Disorders
| | - Vic Velanovich
- Joy McCann Culverhouse Center for Swallowing Disorders.,Division of General Surgery, Morsani College of Medicine University of South Florida, Tampa, Florida, USA
| | - Joel E Richter
- Division of Digestive Diseases and Nutrition.,Joy McCann Culverhouse Center for Swallowing Disorders
| |
Collapse
|
6
|
Slone S, Fleifil S, Anthony S, Green L, Nieman ML, Lorenz J, Tranter M. Abstract 496: Inhibition of the Rna Binding Protein Hur Protects Against Cardiac Ischemia/reperfusion Injury by Reducing Inflammatory Gene Expression. Circ Res 2019. [DOI: 10.1161/res.125.suppl_1.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Despite medical advances, cardiac ischemia/reperfusion (I/R) injury remains a leading cause of morbidity and a huge economic burden in the United States. RNA binding proteins are becoming recognized as potential mediators of cardiac physiology and pathology, but the role of HuR, an RNA binding protein highly expressed in myocytes, in acute cardiac I/R injury is unknown. HuR has been shown in other tissues to be a critical post-transcriptional mediator of pro-inflammatory chemokine and cytokine gene expression, and we have shown HuR to be activated (nuclear-to-cytoplasmic translocation) in cardiomyocytes 2 hours post-ischemia/reperfusion injury.
To address the functional role of HuR in I/R, cardiomyocyte-specific HuR deletion mice (iCM-HuR
-/-
) were subjected to 30 minutes of LAD (left anterior descending) coronary artery ligation followed by 24 hours of reperfusion. In parallel, a separate group of wild-type mice were subjected to 30 minutes ischemia with a pharmacological inhibitor of HuR given just prior to reperfusion. Analysis of infarct size showed a smaller infarct with both HuR genetic deletion (~10% decrease in infarct size compared to control, N=3, P<0.05) and pharmacological inhibition (~11% decrease in infarct size compared to vehicle, N=4, P=0.069). Similarly, HuR inhibition significantly reduced cell death, caspase-3 activity, and inflammatory gene expression in an
in vitro
model of simulated I/R using neonatal rat ventricular myocytes. HuR inhibition results in a significant blunting of IL-6 and TNF-alpha gene expression two hours post-reperfusion
in vivo
, suggesting that HuR activity is necessary for the early induction of inflammatory gene expression networks. In addition, it appears that HuR inhibition attenuates macrophage infiltration following ischemia/reperfusion injury. In conclusion, our results suggest that inhibition of HuR is protective against cardiac I/R injury through a reduction in inflammatory gene expression.
Collapse
|
7
|
Slone S, Fleifil S, Anthony S, Green L, Nieman ML, Lorenz J, Tranter M. Inhibition of the RNA binding protein HuR protects against cardiac ischemia/reperfusion injury by reducing inflammatory gene expression. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.lb515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Samuel Slone
- Department of Pharmacology and Systems PhysiologyUniversity of CincinnatiCincinnatiOH
| | | | | | | | | | - John Lorenz
- Division of Cardiovascular Health and DiseaseUniversity of CincinnatiCincinnatiOH
| | - Michael Tranter
- Department of Internal MedicineUniversity of CincinnatiCincinnatiOH
| |
Collapse
|
8
|
Green LC, Anthony SR, Slone S, Lanzillotta L, Lorenz J, Tranter M. Pharmacological inhibition of Human Antigen R (HuR) blunts fibroblast activation and cardiac fibrosis. FASEB J 2019. [DOI: 10.1096/fasebj.2019.33.1_supplement.817.7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Lisa C Green
- Department of Internal MedicineUniversity of CincinnatiCincinnatiOH
| | - Sarah R Anthony
- Department of Internal MedicineUniversity of CincinnatiCincinnatiOH
| | - Samuel Slone
- Department of Internal MedicineUniversity of CincinnatiCincinnatiOH
| | | | - John Lorenz
- Department of Pharmacology and Systems PhysiologyUniversity of CincinnatiCincinnatiOH
| | - Michael Tranter
- Department of Internal MedicineUniversity of CincinnatiCincinnatiOH
| |
Collapse
|
9
|
Green LC, Anthony SR, Slone S, Lanzillotta L, Nieman ML, Wu X, Robbins N, Jones SM, Roy S, Owens AP, Aube J, Xu L, Lorenz JN, Blaxall BC, Rubinstein J, Benoit JB, Tranter M. Human antigen R as a therapeutic target in pathological cardiac hypertrophy. JCI Insight 2019; 4:121541. [PMID: 30668549 DOI: 10.1172/jci.insight.121541] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2018] [Accepted: 01/14/2019] [Indexed: 01/06/2023] Open
Abstract
RNA binding proteins represent an emerging class of proteins with a role in cardiac dysfunction. We show that activation of the RNA binding protein human antigen R (HuR) is increased in the failing human heart. To determine the functional role of HuR in pathological cardiac hypertrophy, we created an inducible cardiomyocyte-specific HuR-deletion mouse and showed that HuR deletion reduces left ventricular hypertrophy, dilation, and fibrosis while preserving cardiac function in a transverse aortic constriction (TAC) model of pressure overload-induced hypertrophy. Assessment of HuR-dependent changes in global gene expression suggests that the mechanistic basis for this protection occurs through a reduction in fibrotic signaling, specifically through a reduction in TGF-β (Tgfb) expression. Finally, pharmacological inhibition of HuR at a clinically relevant time point following the initial development of pathological hypertrophy after TAC also yielded a significant reduction in pathological progression, as marked by a reduction in hypertrophy, dilation, and fibrosis and preserved function. In summary, this study demonstrates a functional role for HuR in the progression of pressure overload-induced cardiac hypertrophy and establishes HuR inhibition as a viable therapeutic approach for pathological cardiac hypertrophy and heart failure.
Collapse
Affiliation(s)
- Lisa C Green
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and.,Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Sarah R Anthony
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and
| | - Samuel Slone
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and.,Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Lindsey Lanzillotta
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and
| | - Michelle L Nieman
- Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Xiaoqing Wu
- Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA
| | - Nathan Robbins
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and
| | - Shannon M Jones
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and
| | - Sudeshna Roy
- Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
| | - A Phillip Owens
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and
| | - Jeffrey Aube
- Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
| | - Liang Xu
- Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA
| | - John N Lorenz
- Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
| | - Burns C Blaxall
- Department of Pediatrics, Division of Molecular Cardiovascular Biology, Heart Institute, Cincinnati Children's Hospital Medical Center (CCHMC), Cincinnati, Ohio, USA
| | - Jack Rubinstein
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and
| | - Joshua B Benoit
- Department of Biological Sciences, University of Cincinnati, Cincinnati, Ohio, USA
| | - Michael Tranter
- Department of Internal Medicine, Division of Cardiovascular Health and Disease and
| |
Collapse
|
10
|
Owens AP, Robbins N, Saum K, Jones SM, Kirschner A, Woo JG, McCoy C, Slone S, Rothenberg ME, Urbina EM, Tranter M, Rubinstein J. Tefillin use induces remote ischemic preconditioning pathways in healthy men. Am J Physiol Heart Circ Physiol 2018; 315:H1748-H1758. [PMID: 30216115 DOI: 10.1152/ajpheart.00347.2018] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The present study assessed whether tefillin use (tight, nonocclusive, wrapping of the arm) elicits a remote ischemic preconditioning (RIPC)-like effect in subjects with both acute and chronic use. RIPC, created by short bursts of ischemia-reperfusion, has not been successfully taken to the bedside. Several large population studies have found that Orthodox Jewish men (who wear tefillin almost daily) have decreased cardiovascular mortality compared with non-Orthodox counterparts. We hypothesized that tefillin use is a relevant component in triggering a preconditioning effect. Jewish men ( n = 20) were enrolled; 9 men were daily tefillin users (conditioned) and 11 men were nonusers of tefillin as controls (naïve). Subjects were evaluated for adherence to traditional Jewish practice, had vital signs measured, blood drawn for analysis of circulating cytokines and monocyte function, and underwent brachial flow-mediated dilation to evaluate vascular reactivity at baseline (basal) and after 30 min of using tefillin (acute treatment). Under basal conditions, both groups had similar peak systolic velocity (SV), diameter, and flow volume, although the conditioned group had higher SV at 120 s postdeflation ( P = 0.05). Acute tefillin use augmented artery diameter and flow volume in both groups, with conditioned subjects experiencing higher SV than control subjects at 90 and 120 s postdeflation ( P = 0.03 and P = 0.02, respectively). Conditioned subjects had decreased inflammation, monocyte migration and adhesion, and endothelial activation compared with control subjects at baseline. Acute use of tefillin did not significantly alter monocyte function in either group. In this pilot study, acute tefillin use improves vascular function, whereas chronic tefillin use is associated with an anti-inflammatory RIPC-like phenotype. NEW & NOTEWORTHY We hypothesized that tefillin use among Orthodox Jewish men (who practice a nonocclusive leather banding of their nondominant arm) will induce a remote ischemic preconditioning phenotype. Chronic use of tefillin in Orthodox Jewish men was associated with increased systolic velocity and attenuated inflammation and monocyte chemotaxis and adhesion versus Jewish men who do not wear tefillin. Acute use of tefillin in both populations augmented brachial artery diameter and blood flow but not inflammatory profiles compared with baseline.
Collapse
Affiliation(s)
- A Phillip Owens
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio
| | - Nathan Robbins
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio
| | - Keith Saum
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio.,Department of Biomedical Engineering, University of Cincinnati , Cincinnati, Ohio
| | - Shannon M Jones
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio
| | - Akiva Kirschner
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio
| | - Jessica G Woo
- Department of Pediatrics, University of Cincinnati , Cincinnati, Ohio.,Division of Biostatistics and Epidemiology, University of Cincinnati , Cincinnati, Ohio
| | - Connie McCoy
- Department of Pediatrics, University of Cincinnati , Cincinnati, Ohio.,Division of Cardiology, University of Cincinnati , Cincinnati, Ohio
| | - Samuel Slone
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio
| | - Marc E Rothenberg
- Department of Pediatrics, University of Cincinnati , Cincinnati, Ohio.,Division of Allergy and Immunology, University of Cincinnati , Cincinnati, Ohio
| | - Elaine M Urbina
- Department of Pediatrics, University of Cincinnati , Cincinnati, Ohio.,Division of Cardiology, University of Cincinnati , Cincinnati, Ohio
| | - Michael Tranter
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio
| | - Jack Rubinstein
- Division of Cardiovascular Health and Disease, Department of Medicine, University of Cincinnati , Cincinnati, Ohio
| |
Collapse
|
11
|
Green L, Anthony S, Slone S, Lanzillotta L, Nieman M, Wu X, Robbins N, Jones S, Rubinstein J, Lorenz J, Blaxall B, Xu L, Benoit J, Tranter M. Human Antigen R (HuR) as a therapeutic target in pathological cardiac hypertrophy. J Mol Cell Cardiol 2018. [DOI: 10.1016/j.yjmcc.2018.07.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Slone S, Anthony SR, Lanzillotta L, Nieman ML, Green LC, Lorenz JN, Tranter M. Inhibition of the RNA binding protein HuR reduces cardiac cell death following ischemia/reperfusion injury. FASEB J 2018. [DOI: 10.1096/fasebj.2018.32.1_supplement.717.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Samuel Slone
- Department of Pharmacology and Systems PhysiologyUniversity of CincinnatiCincinnatiOH
| | - Sarah R. Anthony
- Department of Internal MedicineDivision of Cardiovascular Health and DiseasesUniversity of CincinnatiCincinnatiOH
| | - Lindsey Lanzillotta
- Department of Internal MedicineDivision of Cardiovascular Health and DiseasesUniversity of CincinnatiCincinnatiOH
| | - Michelle L. Nieman
- Department of Pharmacology and Systems PhysiologyUniversity of CincinnatiCincinnatiOH
| | - Lisa C. Green
- Department of Pharmacology and Systems PhysiologyUniversity of CincinnatiCincinnatiOH
| | - John N. Lorenz
- Department of Pharmacology and Systems PhysiologyUniversity of CincinnatiCincinnatiOH
| | - Michael Tranter
- Department of Internal MedicineDivision of Cardiovascular Health and DiseasesUniversity of CincinnatiCincinnatiOH
| |
Collapse
|
13
|
Kumar S, Chaiswing L, Downes L, Shelton B, Slone S, Derbin E, St. Clair D, St. Clair W. IL-8 and CRP as Predictive Markers in Prostate Cancer. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
Jones S, Robbins N, Saum K, Slone S, Thompson J, Tranter M, Mackman N, Owens AP. Abstract 422: Protease-Activated Receptor 2 is Critical for the Formation and Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol 2017. [DOI: 10.1161/atvb.37.suppl_1.422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective:
Protease-activated receptor 2 (PAR-2)-dependent signaling results in augmented inflammation and has been implicated in the pathogenesis of several autoimmune conditions. While PAR-2 protein is present in coronary atherosclerotic lesions, the relevance of this finding has not been investigated in experimental models. The objective of this study was to determine the effects of PAR-2 on the development of atherosclerosis.
Methods and Results:
Relative expression of PAR-2 is increased in human coronary artery (21 fold) and mouse aortic arch (16 fold) atheromas versus control coronary and aortic arch arteries, respectively (P = 0.001). To determine the effect of PAR-2 deficiency on atherosclerosis, male low density lipoprotein receptor deficient (
Ldlr
-/-
) mice (8-12 weeks old) that were
Par-2
+/+
or
Par-2
-/-
were fed a fat and cholesterol-enriched diet for 12 (n = 10 each group) or 24 weeks (n = 5 each group). PAR-2 deficiency attenuated atherosclerosis in the aortic sinus and aortic root with no effects on total plasma cholesterol concentrations or lipoprotein distributions after 12 (P = 0.000433) and 24 (P = 0.037) weeks. These reductions were attributable to both hematopoietic and non-hematopoietic-derived PAR-2 from analysis of bone marrow experiments (n = 15 for each of 4 chimeric groups; P < 0.05). Mechanistic studies using ex vivo macrophages show that activation of PAR-2 results in augmented foam cell formation and apoptosis with treatment of oxidized low-density lipoprotein in conjunction with decreased expression of the nuclear receptor LXR-alpha and several cholesterol transporters. In addition, PAR-2 activation of ex-vivo cultured vascular smooth muscle cells (VSMCs) augments their transition to a macrophage-like state (after cholesterol treatment) via upregulation of human antigen R (HuR) and resultant stabilization of the transcription factor Krüppel-like factor 4 (KLF4).
Conclusion:
Our results indicate PAR-2 deficiency significantly attenuates the initiation (12 weeks) and reduces the progression (24 weeks) of atherosclerosis potentially via regulation of both lipid efflux from macrophages and the phenotypic modulation of VSMCs.
Collapse
|
15
|
Slone S, Anthony SR, Wu X, Benoit JB, Aube J, Xu L, Tranter M. Activation of HuR downstream of p38 MAPK promotes cardiomyocyte hypertrophy. Cell Signal 2016; 28:1735-41. [PMID: 27521603 DOI: 10.1016/j.cellsig.2016.08.005] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 08/02/2016] [Accepted: 08/08/2016] [Indexed: 10/21/2022]
Abstract
The RNA binding protein Human antigen R (HuR) interacts with specific AU-rich domains in target mRNAs and is highly expressed in many cell types, including cardiomyocytes. However, the role of HuR in cardiac physiology is largely unknown. Our results show that HuR undergoes cytoplasmic translocation, indicative of its activation, in hypertrophic cardiac myocytes. Specifically, HuR cytoplasmic translocation is significantly increased in NRVMs (neonatal rat ventricular myocytes) following treatment with phenylephrine or angiotensin II, agonists of two independent Gαq-coupled GPCRs known to induce hypertrophy. This Gq-mediated HuR activation is dependent on p38 MAP kinase, but not canonical Gq-PKC signaling. Furthermore, we show that HuR activation is necessary for Gq-mediated hypertrophic growth of NRVMs as siRNA-mediated knockdown of HuR inhibits hypertrophy as measured by cell size and expression of ANF (atrial natriuretic factor). Additionally, HuR overexpression is sufficient to induce hypertrophic cell growth. To decipher the downstream mechanisms by which HuR translocation promotes cardiomyocyte hypertrophy, we assessed the role of HuR in the transcriptional activity of NFAT (nuclear factor of activated T cells), the activation of which is a hallmark of cardiac hypertrophy. Using an NFAT-luciferase reporter assay, we show an acute inhibition of NFAT transcriptional activity following pharmacological inhibition of HuR. In conclusion, our results identify HuR as a novel mediator of cardiac hypertrophy downstream of the Gq-p38 MAPK pathway, and suggest modulation of NFAT activity as a potential mechanism.
Collapse
Affiliation(s)
- Samuel Slone
- Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States
| | - Sarah R Anthony
- Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States
| | - Xiaoqing Wu
- Department of Molecular Biosciences, University of Kansas, Lawrence, KS, United States
| | - Joshua B Benoit
- Department of Biological Sciences, McMicken College of Arts and Sciences, University of Cincinnati, Cincinnati, OH, United States
| | - Jeffrey Aube
- Department of Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, United States
| | - Liang Xu
- Department of Molecular Biosciences, University of Kansas, Lawrence, KS, United States
| | - Michael Tranter
- Division of Cardiovascular Health and Disease, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
| |
Collapse
|
16
|
Tranter M, Kraynik S, Anthony SR, Slone S, Nieman ML, John LN, Rubinstein J. Abstract 60: Cardiac-specific Deletion of HuR Reduces Pathological Hypertrophy and Ventricular Remodeling Following Transverse Aortic Constriction. Circ Res 2015. [DOI: 10.1161/res.117.suppl_1.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The RNA binding protein HuR (Human antigen R) interacts with specific AU-rich domains in target mRNAs and is highly expressed in many cell types, including cardiomyocytes. However, the role of HuR in cardiac physiology is largely unknown. Our results show that HuR undergoes cytoplasmic translocation, indicative of its activation, in hypertrophic mouse cardiac myocytes at 8 weeks post-transverse aortic constriction (TAC). To determine the role of HuR in the development of cardiac hypertrophy, we have created a novel mouse model of cardiac myocyte-specific deletion of HuR. While cardiac-specific HuR deletion mice do not show an overt basal phenotype, they have preserved ejection fraction and reduced ventricular remodeling (hypertrophy and chamber dilation) compared to wild-type littermates at 8 weeks following TAC. Furthermore, HuR activation in the hypertrophic heart is strongly co-localized with regions of fibrosis. To this end, we show that HuR knockdown reduced hypertrophy and pro-fibrotic TGF-β gene expression in a phenylephrine treated neonatal rat ventricular myocyte (NRVM) model of hypertrophy. Thus, our results suggest that HuR activation in cardiac myocytes promotes pathogical hypertrophy and initiation of cardiac fibrosis via myocyte expression of TGF-β. These findings are significant as we have identified HuR as a novel mediator of pathological hypertrophy and suggest a pro-fibrotic role as a potential mechanism for this effect.
Collapse
|
17
|
Slone S, Onusko E, Koch S, Singh U, Kraynik S, Tranter M, Rubinstein J. Determining the subcellular localization and function of cardiac TRPV2 Ca
2+
channels through fluorescent microscopy (545.4). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.545.4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Samuel Slone
- INT MED‐Cardiology University of CincinnatiCincinnatiOHUnited States
| | - Evan Onusko
- INT MED‐Cardiology University of CincinnatiCincinnatiOHUnited States
| | - Sheryl Koch
- INT MED‐Cardiology University of CincinnatiCincinnatiOHUnited States
| | - Umesh Singh
- INT MED‐Immunology University of CincinnatiCincinnatiOHUnited States
| | - Steve Kraynik
- INT MED‐Cardiology University of CincinnatiCincinnatiOHUnited States
| | - Michael Tranter
- INT MED‐Cardiology University of CincinnatiCincinnatiOHUnited States
| | - Jack Rubinstein
- INT MED‐Cardiology University of CincinnatiCincinnatiOHUnited States
| |
Collapse
|
18
|
DeSimone C, Elder J, Edwards A, Slone S, Feddock J, Miller R, Baldwin L, van Nagell J, Ueland F. Endometrial cancer lesion size is predictive of disease recurrence and long-term survival. Gynecol Oncol 2013. [DOI: 10.1016/j.ygyno.2013.04.230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
19
|
Croley JJ, Black EP, Romond E, Chambers M, Waynick S, Slone S, Waynick C, Stevens M, Weiss HL, Massarweh SA. Abstract P2-14-05: A phase II study of combined fulvestrant and RAD001 (everolimus) in metastatic estrogen receptor (ER) positive breast cancer after aromatase inhibitor (AI) failure. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-14-05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Fulvestrant is used to treat women with metastatic ER-positive breast cancer after AI failure, but has a short duration of benefit. Pi3K/mTOR signaling has been implicated in preclinical models of fulvestrant resistance and recent trials suggest that everolimus, an oral inhibitor of mTOR, can overcome resistance to other forms of endocrine therapy. We hypothesized that everolimus may delay resistance to fulvestrant and prolong time to progression (TTP).
Methods: We designed a phase II clinical trial of combined fulvestrant and everolimus in postmenopausal women with ER-positive breast cancer who relapsed or experienced metastatic disease progression within 6 months of AI use. Fulvestrant was given at 500 mg IM on day1, 250 mg d14, 250 mg d28, and monthly thereafter. Everolimus was given at 10 mg po daily. Patients were required to have measurable or evaluable disease with preserved performance status and adequate organ function. Primary endpoint is TTP, and secondary endpoints are safety, response rate, clinical benefit rate, and biomarker analysis. A sample size of 40 patients was calculated to meet a median TTP of 7.0 vs. 3.7 months for fulvestrant alone as reported in the EFECT trial. Patients were followed monthly for clinical and toxicity assessment and imaging was obtained every 2 months. Tumor blocks were collected when available and biopsies were offered if disease was accessible.
Results: To date, 30 patients enrolled on study with a median age of 56 years (range 39–85). Most common metastatic disease sites were bone in 26 patients (87%), liver in 19 (63%), and lung in 16 (53%). Prior therapy included tamoxifen in 21 patients (70%), and chemotherapy in 20 (67%), of those 17 were in the adjuvant/neoadjuvant setting. 6 patients (20%) received more than one AI. 2 patients were ruled ineligible immediately after enrollment and starting study treatment, one because of a creatinine level outside the reference range and one because of the need for palliative radiation. Of the remaining 28 patients, 18 discontinued therapy because of disease progression, 3 because of toxicity, 2 upon patient request, and 1 because of unrelated intercurrent illness, with 4 patients currently on therapy. Most common adverse events reported were mucositis in 13 patients (43%) and rash in 11 (36%). Most common laboratory abnormalities were elevated ALT/AST in 18 patients (60%), elevated cholesterol in 13 (43%), and hypokalemia in 13 (43%). The majority of toxicities were grade I/II. Most common grade III toxicities, regardless of attribution, were infection requiring hospitalization in 3 patients (10%), hypokalemia in 3 (10%) and mucositis in 2 (7.4%). There was one grade 4 toxicity reported-hypokalemia. Overall, treatment was reasonably tolerated and toxicities manageable. Efficacy findings, including the primary endpoint of TTP, will be analyzed and presented at the meeting.
Conclusions: Combined everolimus with fulvestrant is feasible and has manageable toxicities in this cohort of women with metastatic ER-positive breast cancer. Detailed efficacy analysis along with updated toxicity data will be presented at the meeting.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-14-05.
Collapse
Affiliation(s)
- JJ Croley
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - EP Black
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - E Romond
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - M Chambers
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - S Waynick
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - S Slone
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - C Waynick
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - M Stevens
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - HL Weiss
- University of Kentucky and Markey Cancer Center, Lexington, KY
| | - SA Massarweh
- University of Kentucky and Markey Cancer Center, Lexington, KY
| |
Collapse
|
20
|
Seamon L, Cohn D, Carlson M, Elder J, Ferda A, Taege S, Ueland F, Shelton B, Slone S, DeSimone C. Selective versus systematic lymphadenectomy for endometrial cancer: A cohort survival analysis. Gynecol Oncol 2012. [DOI: 10.1016/j.ygyno.2011.12.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
21
|
Dignan M, Shelton B, Pearce K, Schoenberg N, Tolle C, Slone S. P2-62 Early detection of colorectal cancer in the US in Appalachia. Br J Soc Med 2011. [DOI: 10.1136/jech.2011.142976h.97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
22
|
Rinehart JJ, Arnold SM, Kloecker GH, Lim A, Zaydan MA, Slone S, Croley J, Kvale E. Randomized phase II trial of carboplatin (C) and gemcitabine (G) with or without dexamethasone (Dex) in patients (pts) with stage IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Slone S, Reynolds L, Gall S, Peiper S, Martin A, Ackermann D, O'Connor D. Localization of chromogranin, synaptophysin, serotonin, and CXCR2 in neuroendocrine cells of the minor vestibular glands: an immunohistochemical study. Int J Gynecol Pathol 1999; 18:360-5. [PMID: 10542945 DOI: 10.1097/00004347-199910000-00011] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Sections of vulvar tissue containing minor vestibular glands (15 sections from 14 women with vulvar vestibulitis syndrome and six control sections from five asymptomatic women) were immunohistochemically stained with antibodies against chromogranin, synaptophysin, serotonin, and CXCR2. The degree of inflammation in vestibular tissue from women with and without vulvar vestibulitis syndrome was not significantly different. All vulvar minor vestibular glands contained neuroendocrine cells that expressed chromogranin to some degree. Only one case failed to express synaptophysin. The number of cells expressing chromogranin and synaptophysin was the same regardless of the degree of inflammation. However, moderate to severe inflammation was associated with a statistically significant increase in the number of cells expressing serotonin (p < 0.001) and CXCR2 (p < 0.02). It is concluded that neuroendocrine cells are present within minor vestibular glands of the vulva. The number of cells expressing the inflammatory mediator serotonin and CXCR2, the shared interleukin-8 receptor, are upregulated with inflammation. Chronic inflammation is a normal finding in vestibular tissue and does not serve as a histologic marker for vulvar vestibulitis.
Collapse
Affiliation(s)
- S Slone
- Department of Pathology, University of Louisville School of Medicine, Kentucky 40292, USA
| | | | | | | | | | | | | |
Collapse
|
24
|
Slone S, O'Connor D. Scrotal leiomyomas with bizarre nuclei: a report of three cases. Mod Pathol 1998; 11:282-7. [PMID: 9521476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
We discuss here three cases of scrotal leiomyoma with bizarre nuclei. The patients, ranging in age from 44 to 58 years, presented with painless scrotal masses that were clinically diagnosed as cysts. Clinical follow-up, available for two of the patients, revealed no evidence of local recurrence or distant metastasis 5 years after resection. The tumors were well circumscribed and ranged from 2 to 3 cm in maximal diameter. They were characterized by interlacing fascicles of spindle-shaped cells with pleomorphic nuclei. Nuclei were large and multilobulated with hyperchromatic chromatin and macronucleoli. Multinucleated tumor cells were infrequent. Intranuclear invagination of eosinophilic globules of cytoplasm produced pseudonucleoli. There was no mitotic activity. Immunohistochemically, the tumor cells expressed vimentin, desmin, smooth muscle actin, and muscle-specific actin, but not cytokeratin, neurofilament, or glial fibrillary acidic protein. In contrast to scrotal leiomyosarcomas, scrotal leiomyomas with bizarre nuclei are not hypercellular, and they lack mitotic activity.
Collapse
Affiliation(s)
- S Slone
- Department of Pathology, School of Medicine, University of Louisville, Kentucky 40292, USA
| | | |
Collapse
|
25
|
Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR, Waclawiw M, Fineberg SE. The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas 1997; 27:261-74. [PMID: 9288699 DOI: 10.1016/s0378-5122(97)00041-8] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVE To assess the efficacy of unopposed estrogen, and three estrogen/progestin regimens on selected heart disease risk factors among adherent women and to contrast those results with efficacy among all women in the PEPI study. DESIGN A 3-year, multicenter, randomized, double-blinded, placebo-controlled clinical trial. PARTICIPANTS A total of 847 healthy postmenopausal women aged 45 to 64 years of age with no known contraindication to hormone therapy, who attended their 36 month clinical visit. INTERVENTION Participants were randomized in equal numbers to one of the following treatments: (1) placebo; (2) conjugated equine estrogen (CEE) 0.625 mg daily; (3) CEE 0.625 daily plus medroxyprogesterone acetate (MPA) 10 mg, days 1-12; (4) CEE 0.625 daily plus MPA 2.5 mg daily; or (5) CEE 0.625 daily plus micronized progesterone (MP) 200 mg, days 1-12. ANALYSIS Analyses are based on adherent women, where adherence is defined as taking at least 80% of pills at each 6-month visit. RESULTS Adherence rates were high in all groups except women with a uterus assigned to unopposed CEE. The difference in HDL-C levels resulting from the CEE vs. CEE+MP was approximately three times larger than in the intent-to-treat analyses, reaching statistical significance (P < 0.05). In each active treatment, LDL-C decreased 10-15%. Triglycerides increased 15-20% in each opposed CEE arm and over 25% in the CEE only arm; this difference was not statistically significant. Fibrinogen increased by 7% among placebo adherers, but decreased or remained fairly stable among the active arm adherers. Systolic blood pressure increased 3-5% in all treatment arms. Women adherent to the CEE+MPA arms had twice the increase of 2 h glucose levels as women adherent to CEE only, or CEE+MP (8-9% vs. 3-4%). Two-hour insulin levels decreased 3-12% for all arms. The patterns of change for fibrinogen, SBP, 2 h glucose and insulin were similar to those from the intent-to-treat analyses. CONCLUSIONS In analyses limited to adherent women, all active treatments, compared to placebo, continued to have similar and favorable effects on LDL-cholesterol and fibrinogen and no significant effects on blood pressure or insulin levels. Given the overall high adherence rates in PEPI, the results are similar to the intent-to-treat analyses, as expected. Only the trend of HDL-C to have a larger increase in the CEE only arm (in the intent-to-treat analyses) gained statistical significance in analyses restricted to adherers.
Collapse
Affiliation(s)
- E Barrett-Connor
- Department of Family and Preventive Medicine, University of California, San Diego, La Jolla 92093-0607, USA
| | | | | | | | | | | | | | | |
Collapse
|